Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina


March 19, 2010
126 Pages - SKU: DFMN6281190
License type:
Table of Contents Related Reports
Overview
Catalyst
Summary
About Datamonitor healthcare
About the Infectious Diseases pharmaceutical analysis team
Executive Summary
Scope of the analysis
Datamonitor insight into vaccines in emerging markets (Latin America)
Related reports
Upcoming reports
Table of Contents
1. Overview of the three main Latin American Emerging markets for vaccines
Key findings
Brazil and Mexico are promising potential markets for vaccine developers due to their large birth cohorts and growing population sizes
The increasing wealth in Latin America has led to the emergence of a promising private sector market for vaccines
There is a large unmet need for vaccines against endemic diseases in Latin America
Vaccination coverage and recommendations vary across the key emerging Latin American markets
There are significant differences between the vaccines markets of Brazil, Mexico and Argentina
2. Brazil
Key findings
General characteristics
Demographics
Economics
Healthcare expenditure and access
The Brazilian vaccines market
Historic development
Current market situation
Key stakeholders in Brazil's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in Brazil
General overview
Multinational corporations
GlaxoSmithKline
Sanofi Pasteur
Merck & Co, Wyeth/Pfizer, Novartis
Local vaccine players
Fiocruz/Bio-Manguinhos
Instituto Butantan
Key future target indications
SWOT analysis of Brazil as a target market for vaccine producers
Best strategy for market penetration
3. Mexico
Key findings
General characteristics
Demographics
Economics
Healthcare expenditure and access
The Mexican vaccines market
Historic development
Current market situation
Key stakeholders in Mexico's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in Mexico
General overview
Multinational corporations
Sanofi Pasteur
Novartis
Merck & Co
GlaxoSmithKline
Wyeth/Pfizer
Local vaccine players
Birmex
Key future target indications
SWOT analysis of Mexico as a target market for vaccine producers
Best strategy for market penetration
4. Argentina
Key findings
General characteristics
Demographics
Economics
Healthcare expenditure and access
The Argentinean vaccines market
Historic development
Current market situation
Key stakeholders in Argentina's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in Argentina
General overview
Multinational corporations
Sanofi Pasteur
GlaxoSmithKline
Novartis
Merck & Co
Wyeth/Pfizer
Local vaccine players
Key future target indications
SWOT analysis of Argentina as a target market for vaccine producers
Best strategy for market penetration
Bibliography
Journals
Websites
Appendix
Contributing experts
Conferences attended
Report methodology
About Datamonitor
About Datamonitor Healthcare
About the Infectious Diseases analysis team
Key therapy team members
Hedwig Kresse, Lead Analyst, Infectious Diseases
Disclaimer
List of Tables
Table 1: Overview: vaccines recommended as part of the national immunization schedules in Brazil, Mexico and Argentina, 2009
Table 2: Pan American Health Organization (PAHO) revolving fund vaccine prices, 2009
Table 3: Brazil: key economic indicators, 2007-09
Table 4: Brazil: healthcare expenditure indicators, 2006
Table 5: Brazil: key health system indicators, 2006
Table 6: Brazil: top 10 causes of mortality, 2004
Table 7: Brazil: vaccination recommendations, 2009
Table 8: Brazil: administered vaccine doses by indication, 2005-09
Table 9: Brazil: position of the five key Western vaccine players, 2010
Table 10: Brazil: overview of key local vaccine players, 2010
Table 11: Fiocruz/Bio-Manguinhos: human vaccine portfolio overview, 2010
Table 12: Fiocruz/Bio-Manguinhos: key vaccine deals and alliances, 2010
Table 13: Instituto Butantan: human vaccine portfolio overview, 2010
Table 14: Instituto Butantan: key vaccine deals and alliances, 2010
Table 15: SWOT analysis of Brazil as vaccine market, 2010
Table 16: Mexico: key economic indicators, 2007-09
Table 17: Mexico: healthcare expenditure indicators, 2006
Table 18: Mexico: key health system indicators, 2004
Table 19: Mexico: top 10 causes of mortality, 2004
Table 20: Mexico: vaccination recommendations, 2009
Table 21: Mexico: authorized vaccines, November 2009
Table 22: Mexico: position of the five key Western vaccine players, 2010
Table 23: Birmex: human vaccine portfolio overview, 2010
Table 24: Birmex: key vaccine deals and alliances, 2010
Table 25: SWOT analysis of Mexico as vaccine market, 2010
Table 26: Argentina: key economic indicators, 2007-09
Table 27: Argentina: healthcare expenditure indicators, 2006
Table 28: Argentina: key health system indicators, 2004
Table 29: Argentina: top 10 causes of mortality, 2004
Table 30: Argentina: estimated number of vaccine doses distributed for key indications, 2010
Table 31: Argentina: vaccination recommendations, 2009
Table 32: Argentina: authorized vaccines, 2010
Table 33: Argentina: position of the five key Western vaccine players, 2010
Table 34: SWOT analysis of Argentina as vaccine market, 2010
List of Figures
Figure 1: Overview: total population size, Brazil, Mexico, Argentina, the US and the five major EU markets, 1995-2020
Figure 2: Overview: birth cohort size, Brazil, Mexico, Argentina, the US and the five major EU markets, 1995-2020
Figure 3: Overview: gross domestic product (GDP) per capita, Brazil, Mexico, Argentina, the US and the five major EU markets, 2007-09
Figure 4: Overview: healthcare spend per capita and private expenditure on health in Brazil, Mexico, Argentina, the US and the five major EU markets, 2006
Figure 5: Overview: distribution of key endemic diseases in Latin America
Figure 6: Overview: coverage for key vaccinations in Brazil, Mexico and Argentina, 2008
Figure 7: Market shares of key Western vaccine companies in Latin America, 2008
Figure 8: Overview: estimates of the market size for human vaccines in Brazil, Mexico and Argentina, 2008/2009
Figure 9: National versus external vaccine financing, Latin America, 1987-2006
Figure 10: Overview: key domestic vaccine players in Brazil, Mexico and Argentina, 2010
Figure 11: Overview: key vaccine market characteristics in Brazil, Mexico and Argentina, 2010
Figure 12: Brazil: overview of the vaccine landscape, 2010
Figure 13: Brazil: population growth, 1995-2020
Figure 14: Brazil: population spread by age group, 2010 versus 2020
Figure 15: Brazil: mortality of children <5 years of age, 1995-2020
Figure 16: Brazil: timeline of introduction of key vaccines into the public immunization schedule, 1973-2010
Figure 17: Brazil: Programa Nacional de Imunizações (PNI), vaccine purchase budget, 1995-2007
Figure 18: Brazil: vaccine imports by indication, 2005-09
Figure 19: Brazil: vaccine imports by country of origin, 2005-09
Figure 20: Brazil: vaccination schedule published by Ministério da Saúde , 2009
Figure 21: Brazil: vaccination schedule published by Associação Brasileira de Imunizações, 2009
Figure 22: Brazil: vaccination coverage, 2004-08
Figure 23: Brazil: administered vaccine doses by indication, 2005-09
Figure 24: Brazil: local vaccine production versus imports for public sector vaccines, 1996-2000
Figure 25: Brazil: contribution of multinational vaccine makers to product supply for private sector immunization, 2001
Figure 26: Brazil: Sanofi Pasteur net vaccine sales, 2005-09
Figure 27: Share of Fiocruz/Bio-Manguinhos among Brazilian vaccine suppliers for the National Immunization Program; 2001-07
Figure 28: Fiocruz/Bio-Manguinhos: vaccine sales 2001-07
Figure 29: Fiocruz/Bio-Manguinhos: exported doses of yellow fever vaccine, 2001-07
Figure 30: Brazil: key future target vaccine indications, 2010
Figure 31: Mexico: overview of the vaccine landscape, 2010
Figure 32: Mexico: population growth, 1995-2020
Figure 33: Mexico: population spread by age group, 2010 versus 2020
Figure 34: Mexico: mortality of children <5 years of age, 1995-2020
Figure 35: Mexico: timeline of introduction of key vaccines into the public immunization schedule, 1951-2008
Figure 36: Mexico: applied vaccine doses by indication, 2007
Figure 37: Mexico: applied vaccine doses by indication and month, 2007
Figure 38: Mexico: applied vaccine doses by place of administration, 2007
Figure 39: Mexico: vaccination schedule, 2009
Figure 40: Mexico: vaccination coverage, 2004-08
Figure 41: Mexico: key future target vaccine indications, 2010
Figure 42: Argentina: overview of the vaccine landscape, 2010
Figure 43: Argentina: population growth, 1995-2020
Figure 44: Argentina: population spread by age group, 2010 versus 2020
Figure 45: Argentina: mortality of children <5 years of age, 1995-2020
Figure 46: Argentina: timeline of introduction of key vaccines into the public immunization schedule
Figure 47: Argentina: vaccination schedule, 2009
Figure 48: Argentina: vaccination coverage, 2004-08
Figure 49: Argentina: vaccination coverage by region, 2007
Figure 50: Argentina: key future target vaccine indications, 2010
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Vaccines Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!